Vaxart, Inc.

Equities

VXRT

US92243A2006

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.7097 ^USD	+7.79%		-6.07%	+23.90%

Mar. 14	Vaxart, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 14	Transcript : Vaxart, Inc., 2023 Earnings Call, Mar 14, 2024

Vaxart, Inc. Announces Resignation of Andrei Floroiu as President and Director

January 16, 2024 at 09:22 am EST

Vaxart, Inc. announced a change in management. Effective immediately Andrei Floroiu, President and Chief Executive Officer of Vaxart, has announced his resignation from his positions with Vaxart as President and Director on Vaxart?s Board of Directors.

Latest news about Vaxart, Inc.

Vaxart, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Transcript : Vaxart, Inc., 2023 Earnings Call, Mar 14, 2024	Mar. 14
Vaxart Appoints Steven Lo as Chief Executive; Shares Fall	Mar. 06	MT
Vaxart, Inc. Announces Chief Executive Officer Changes	Mar. 06	CI
Vaxart, Inc. Announces Management Appointments	Mar. 06	CI
North American Morning Briefing : Stock Futures -2-	Feb. 01	DJ
B. Riley Upgrades Vaxart to Buy From Neutral, Lifts PT to $2 From $1.50	Jan. 31	MT
Vaxart Secures $9.3 Million Award for Phase 2b COVID-19 Pill Study	Jan. 19	MT
Vaxart to Raise $10 Million From RA Capital Management; Shares Rise	Jan. 16	MT
Vaxart, Inc. Announces CEO Changes	Jan. 16	CI
Vaxart, Inc. Announces Resignation of Andrei Floroiu as President and Director	Jan. 16	CI
Vaxart, Inc. Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers	Dec. 21	CI
Transcript : Vaxart, Inc., Q3 2023 Earnings Call, Nov 02, 2023	Nov. 02
Vaxart, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Earnings Flash (VXRT) VAXART Posts Q3 Revenue $2.1M	Nov. 02	MT
Vaxart Doses First Subject in Phase 1 Trial of its Norovirus Vaccine Candidate in Lactating Mothers	Nov. 02	CI
Vaxart Says Topline Data From Phase 2 Challenge Study of Monovalent Norovirus Vaccine Meets 5 of 6 Endpoints	23-09-06	MT
Transcript : Vaxart, Inc. - Special Call	23-09-06
Vaxart Announces Topline Data from the Phase 2 Challenge Study of Its Monovalent Norovirus Vaccine Candidate	23-09-06	CI
Cantor Fitzgerald Adjusts Price Target on Vaxart to $4 From $6, Maintains Overweight Rating	23-08-07	MT
Vaxart, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Transcript : Vaxart, Inc., Q2 2023 Earnings Call, Aug 03, 2023	23-08-03
Earnings Flash (VXRT) VAXART Reports Q2 Revenue $1.4M, vs. Street Est of $0.08M	23-08-03	MT
Certain Warrants of Vaxart, Inc. are subject to a Lock-Up Agreement Ending on 23-JUL-2023.	23-07-22	CI
Certain Restricted Stock Units of Vaxart, Inc. are subject to a Lock-Up Agreement Ending on 23-JUL-2023.	23-07-22	CI

Chart Vaxart, Inc.

Duration

Period

More charts

Company Profile

Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Vaxart, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.7097 USD

Average target price

5 USD

Spread / Average Target

+604.52%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VAXART, INC.	+23.90%	126M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs